The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MEHC.Q | -25.81% | N/A | N/A | -98% |
| S&P | +19.89% | +109.18% | +15.89% | +91% |
23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. It provides direct access to genetic information with multiple Food and Drug Administration authorizations for genetic health risk reports. The company operates under the Consumer and Research Services segment, and the Therapeutics segment. The firm’s research platform has generated publications on the genetic underpinnings of a range of diseases, conditions, and traits. The platform also powers the 23andMe therapeutics group, pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in South San Francisco, CA.
Is altruism a good idea for an unprofitable capitalistic enterprise?
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $25.42M | -37.1% |
| Gross Profit | $9.46M | -35.8% |
| Gross Margin | 37.22% | 0.8% |
| Market Cap | $136.61M | -28.8% |
| Market Cap / Employee | $0.52M | 0.0% |
| Employees | 265 | -54.5% |
| Net Income | -$23.83M | 65.7% |
| EBITDA | -$26.64M | 59.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $40.25M | -76.5% |
| Accounts Receivable | $1.23M | 11.6% |
| Inventory | 13.4 | -9.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.12M | -99.8% |
| Short Term Debt | $26.98M | 200.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -84.53% | 17.4% |
| Return On Invested Capital | 88.25% | 172.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$29.04M | 33.5% |
| Operating Free Cash Flow | -$28.99M | 33.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.76 | 0.82 | 0.32 | -5.09 | -600.38% |
| Price to Sales | 0.92 | 0.41 | 0.11 | 0.78 | -19.96% |
| Price to Tangible Book Value | 38.16 | 1.61 | 1.35 | -1.90 | -106.69% |
| Enterprise Value to EBITDA | -2.32 | -3.49 | 0.22 | -4.62 | 216.44% |
| Return on Equity | -169.2% | -169.0% | -324.1% | -430.3% | 179.06% |
| Total Debt | $71.69M | $60.54M | $7.51M | $27.10M | -63.46% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
